LAWSUITS NEWS & LEGAL INFORMATION
Search Results for
Sort by relevance 2,441 pages found matching data breach- FDA Advisory Committee Schedules Hearing on SSRIs and Suicide
Dec-5-06 Washington DC: The FDA's Psychopharmacologic Drugs Advisory Committee will hold a public hearing on December 13, 2006, to review the adult selective serotonin reuptake inhibitor (SSRI) studies on the increased risk of suicide associated with the antidepressants. The panel is expected to vote on whether the risk of suicidality in adults should be inclu... - Biggest Off-Label Drug Marketing Scheme in History - Part II
Dec-1-06 [ Read Part I ] Washington DC: In fairness to off-label prescribing doctors, until recently, studies that showed SSRIs were ineffective and dangerous when used by children were kept hidden and thus, the data made available to physicians painted a rosy, but false, picture of success with SSRIs. And up until recently, many doctors were not even awar... - Biggest Off-Label Drug Marketing Scheme in US History - Part I
Nov-30-06 Washington, DC: The promotion and sale of two classes of psychiatric drugs, the atypical antipsychotics and selective serotonin reuptake inhibitors antidepressants (SSRIs), will go down in history as the most successful off-label marketing scheme of all time. But unfortunately, before the illegal scheme takes its rightful place in the law books, a lot m... - An interview with Trasylol lawyer George Otstott
Nov-28-06 Trasylol spells big profits for the drug manufacturer Bayer AG, but at what cost to its recipients? For countless patients who were given Trasylol during open heart surgery, it has meant renal failure and other severe, often fatal, side affects. Trasylol is administered during open heart surgery. It works to slow or prevent bleeding, and is used to reduce... - SSRI Warning to Pregnant Women
Nov-22-06 Up to 20 percent of women have clinical depression at some time during their lives, and in many women, depression does not improve during pregnancy. Most commonly prescribed antidepressants are known as Selective Serotonin Re-uptake Inhibitors (SSRIs). In May 2005, researchers from the University of Pittsburgh estimated in the Journal of American Medica... - Big Pharma's Battle Over Direct to Consumer Advertising
Nov-21-06 Big Pharma has Americans running to the doctor demanding the latest advertised drug to treat the latest promoted disorder based on the latest commercial they see on TV. According to a report by CBS News on October 22, 2006, the United States makes up just 5 percent of the world's population, "but it accounts for a whopping 42 percent of the world's spen... - FDA's Preemption Gift to Big Pharma
Nov-20-06 Washington, DC: An item sure to end up on the chopping block with the Democrats back in power, is the Bush administration's multi-billion dollar gift to Big Pharma, that bars people who have been injured by drugs approved by the FDA from suing the drug's maker in state courts. Under the FDA's federal preemption position, victims injured by dangerous dru... - Unscientific Depression Screenings and Front Groups Boost SSRI Sales
Nov-10-06 USA: Prior to the arrival of the selective serotonin reuptake inhibitor antidepressants (SSRIs) on the market, depression was estimated to affect only 100 people per million. And those 100 people per million sought help from a medical professional trained in psychiatry and the treatment of depression. Since the introduction of SSRIs, rates for dep... - Cablevision Systems Corp. New York Knicks Breach of Contract Settlement
New York, NY: The New York Knicks fired coach Larry Brown after the basketball team went 23-59 in his first and only season in New York. The 66-year-old had $41 million and four years left on his contract and therefore filed a breach of contract lawsuit against the owners of the team. Brown was paid $10 million for his first year and Cablevision Systems... - ACE Inhibitors and Birth Defects - More Expensive and Less Effective
Nov-9-06 Boston, MA: About one in every four American adults has high blood pressure which is a major risk factor for heart and kidney disease, as well as stroke and heart failure, but often occurs with no warning signs. Blood pressure is the force of blood pushing against blood vessel walls. The heart pumps blood into the arteries which carry the blood througho... - Paxil, Pregnancy and Birth Defects
Nov-9-06 Newfoundland, PA "My psychiatrist prescribed Paxil when I was three months pregnant," says Jaime Curtis. "I feel like it is my fault that I did this to my kid; it just breaks my heart when he can't breathe." Jaime was never told about Paxil's link to birth defects. "I had a normal pregancy, just like my other two, and Geoni was born just five days... - Bausch & Lomb Fails to Warn About Dangers of ReNu Contact Lens Solution
Nov-8-06 Greenville, SC: ReNu with MoistureLoc solution has been widely used for the storing, wetting and cleaning of soft contact lenses. But here once again, a drug company has left a product on the market, with no warning to consumers, long after it was aware that serious side effects were developing in people using the product. According to the FDA, cluste... - Stockbroker Arbitration: Protecting Yourself
Nov-7-06 Los Angeles, CA: If an investor feels his losses were the result of negligent actions on the part of his stockbroker , rather than the vagaries of the market, he can file for arbitration to try to recover those losses. Many contracts between investors and brokers require the investors to submit such disputes with their brokers to arbitration. Furth... - Ketek: A Timeline of Lies
Nov-3-06 Washington, DC Despite information indicating that using Ketek (telithromycin) carried a serious risk of liver disease and other problems, the US Food and Drug Administration (FDA) approved the antibiotic for sale in April, 2004. This occurred even though evidence that the drug was effective was unreliable at best and fraudulent at worst. Use of Ke... - Many Kaiser Kidney Transplant Patients Still In Limbo
Nov-2-06 San Francisco, CA: In May 2006, following reports by the LA Times and CBS News, Kaiser Permanente closed its 2-year-old San Francisco kidney transplant program amidst allegations that it failed to properly transfer patients on waiting lists, leading to missed opportunities for transplants and patients having to undergo years of unnecessary and grueling... - ReNu with MoistureLoc: Consumers Still at Risk
Nov-1-06 San Diego, CA: Despite being recalled in April of this year, ReNu with MoistureLoc contact lens solution was still recording a two percent market share into September, indicating that the product was still available for sale in some stores long after the recall. This market data calls into question whether or not manufacturer Bausch and Lomb was agg... - Benzene Litigation Similar to Early Days of Asbestos and Tobacco
Nov-1-06 Los Angeles, CA: Legal analysts say that the recent surge of benzene lawsuits is beginning to resemble the early days of asbestos and tobacco litigation. CFO Magazine reports that company CFOs and corporate attorneys "foresee a flood tide of benzene suits, including cases that have nothing to do with occupational exposure." CFO quotes Insurance Inf... - Western Michigan University Former President Wrongful Termination Settlement
Kalamazoo, MI: On August 15, 2006 the university's board terminated Judith Bailey's contract as president of the university, citing unsatisfactory performance based on continued enrollment drops and budgetary issues. Bailey filed a wrongful termination and breach of contract lawsuit against the school. Western Michigan University's Board of Trustees una... - Attorney Predicts Five Thousand Lawsuits Against Guidant
Oct-27-06 Boston, MA: On October 18, 2006, Boston Scientific announced financial earnings for the third quarter 2006, in a press release and reported net sales of $2.026 billion as compared to $1.511 billion for the third quarter of 2005, an increase of 34%. The increase, Boston said, was primarily attributable to the inclusion of $491 million of net sales from... - Oops - Bayer forgot to tell FDA about Lethal Side Effects of Trasylol
Oct-26-06 Washington, DC: On September 29, 2006, the New York Times reported that Bayer "failed to reveal to federal drug officials the results of a large study suggesting that a widely used heart-surgery medicine might increase the risks of death and stroke," citing an FDA announcement. That drug is aprotinin, marketed as Trasylol. Bayer's memory lapse...